Inhibition of lapatinib-induced kinome reprogramming in ERBB2-positive breast cancer by targeting BET family bromodomains

Cell Reports

Volumn 11, Issue 3, 2015, Pages 390-404

  Stuhlmiller, Timothy J ^a   Miller, Samantha M ^a   Zawistowski, Jon S ^a   Nakamura, Kazuhiro ^a   Beltran, Adriana S ^a   Duncan, James S ^a   Angus, Steven P ^a   Collins, Kyla A L ^b   Granger, Deborah A ^a   Reuther, Rachel A ^a   Graves, Lee M ^a   Gomez, Shawn M ^b   Kuan, Pei Fen ^c   Parker, JoelS ^a   Chen, Xin ^a   Sciaky, Noah ^a   Carey, LisaA ^a   Earp, H Shelton ^a   Jin, Jian ^d   Johnson, Gary L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c IL   (United States)

^d University of North Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; LAPATINIB; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ARTICLE; BREAST CANCER; CHROMATIN; CONTROLLED STUDY; DDR1 GENE; DOWNSTREAM PROCESSING; ENZYME ACTIVATION; ERBB2 GENE; ERBB3 GENE; FGFR GENE; GENETIC TRANSCRIPTION; IGF1R GENE; MET GENE; NUCLEAR REPROGRAMMING; ONCOGENE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN TARGETING; SIGNAL TRANSDUCTION; BREAST TUMOR; DNA MICROARRAY; DRUG RESISTANCE; FEMALE; HUMAN; MASS SPECTROMETRY; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; METABOLISM; PHYSIOLOGY; POLYMERASE CHAIN REACTION; PROTEOMICS; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MASS SPECTROMETRY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; PROTEIN KINASE INHIBITORS; PROTEOMICS; QUINAZOLINES; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84928203220     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.03.037     Document Type: Article

References (22)

1. Allen-Petersen B.L., Carter C.J., Ohm A.M., Reyland M.E. Protein kinase Cδ is required for ErbB2-driven mammary gland tumorigenesis and negatively correlates with prognosis in human breast cancer. Oncogene 2014, 33:1306-1315.
2. Amin D.N., Sergina N., Ahuja D., McMahon M., Blair J.A., Wang D., Hann B., Koch K.M., Shokat K.M., Moasser M.M. Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci. Transl. Med. 2010, 2:ra7.
3. Azuma K., Tsurutani J., Sakai K., Kaneda H., Fujisaka Y., Takeda M., Watatani M., Arao T., Satoh T., Okamoto I., et al. Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure. Biochem. Biophys. Res. Commun. 2011, 407:219-224.
4. Chandarlapaty S., Sawai A., Scaltriti M., Rodrik-Outmezguine V., Grbovic-Huezo O., Serra V., Majumder P.K., Baselga J., Rosen N. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011, 19:58-71.
5. Delmore J.E., Issa G.C., Lemieux M.E., Rahl P.B., Shi J., Jacobs H.M., Kastritis E., Gilpatrick T., Paranal R.M., Qi J., et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146:904-917.
6. Devaiah B.N., Lewis B.A., Cherman N., Hewitt M.C., Albrecht B.K., Robey P.G., Ozato K., Sims R.J., Singer D.S. BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain. Proc. Natl. Acad. Sci. USA 2012, 109:6927-6932.
7. Duncan J.S., Whittle M.C., Nakamura K., Abell A.N., Midland A.A., Zawistowski J.S., Johnson N.L., Granger D.A., Jordan N.V., Darr D.B., et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 2012, 149:307-321.
8. Garrett J.T., Olivares M.G., Rinehart C., Granja-Ingram N.D., Sánchez V., Chakrabarty A., Dave B., Cook R.S., Pao W., McKinely E., et al. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc. Natl. Acad. Sci. USA 2011, 108:5021-5026.
9. Huang X., Gao L., Wang S., McManaman J.L., Thor A.D., Yang X., Esteva F.J., Liu B. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer Res. 2010, 70:1204-1214.
10. Huang C., Park C.C., Hilsenbeck S.G., Ward R., Rimawi M.F., Wang Y.C., Shou J., Bissell M.J., Osborne C.K., Schiff R. β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Res. 2011, 13:R84.
11. Jang M.K., Mochizuki K., Zhou M., Jeong H.S., Brady J.N., Ozato K. The bromodomain protein Brd4 is a positive regulatory component ofP-TEFb and stimulates RNA polymerase II-dependent transcription. Mol. Cell 2005, 19:523-534.
12. Johannessen C.M., Johnson L.A., Piccioni F., Townes A., Frederick D.T., Donahue M.K., Narayan R., Flaherty K.T., Wargo J.A., Root D.E., Garraway L.A. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature 2013, 504:138-142.
13. Li B.S., Ma W., Jaffe H., Zheng Y., Takahashi S., Zhang L., Kulkarni A.B., Pant H.C. Cyclin-dependent kinase-5 is involved in neuregulin-dependent activation of phosphatidylinositol 3-kinase and Akt activity mediating neuronal survival. J.Biol. Chem. 2003, 278:35702-35709.
14. Rexer B.N., Arteaga C.L. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit. Rev. Oncog. 2012, 17:1-16.
15. Rexer B.N., Ham A.J., Rinehart C., Hill S., Granja-Ingram Nde.M., González-Angulo A.M., Mills G.B., Dave B., Chang J.C., Liebler D.C., Arteaga C.L. Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. Oncogene 2011, 30:4163-4174.
16. Rodrik-Outmezguine V.S., Chandarlapaty S., Pagano N.C., Poulikakos P.I., Scaltriti M., Moskatel E., Baselga J., Guichard S., Rosen N. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov. 2011, 1:248-259.
17. Serra V., Scaltriti M., Prudkin L., Eichhorn P.J., Ibrahim Y.H., Chandarlapaty S., Markman B., Rodriguez O., Guzman M., Rodriguez S., et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 2011, 30:2547-2557.
18. Singleton K.R., Kim J., Hinz T.K., Marek L.A., Casás-Selves M., Hatheway C., Tan A.C., DeGregori J., Heasley L.E. A receptor tyrosine kinase network composed of fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, and hepatocyte growth factor receptor drives growth and survival of head and neck squamous carcinoma cell lines. Mol. Pharmacol. 2013, 83:882-893.
19. Sun C., Wang L., Huang S., Heynen G.J., Prahallad A., Robert C., Haanen J., Blank C., Wesseling J., Willems S.M., et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 2014, 508:118-122.
20. Yang Z., Yik J.H., Chen R., He N., Jang M.K., Ozato K., Zhou Q. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol. Cell 2005, 19:535-545.
21. Zhang S., Huang W.C., Li P., Guo H., Poh S.B., Brady S.W., Xiong Y., Tseng L.M., Li S.H., Ding Z., et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat. Med. 2011, 17:461-469.
22. Zhang Z., Wang J., Ji D., Wang C., Liu R., Wu Z., Liu L., Zhu D., Chang J., Geng R., et al. Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer. Clin. Cancer Res. 2014, 20:4559-4573.